HOME >> BIOLOGY >> NEWS
Mouse mimics chronic leukemia, will aid drug development

logy, immunology and medical genetics and director of human cancer genetics at the OSUCCC-James.

Croce and his laboratory developed the mouse strain in 2002. The researchers engineered the animal so that key immune cells called B lymphocytes, or B cells, overproduce a protein called TCL-1. This overproduction causes the CLL-like disease, which develops about a year after birth, though how it does so is still unknown.

Human CLL is also a cancer of B cells, but it involves many chromosome and gene changes. Byrd and his laboratory are currently investigating whether human CLL cells also have high TCL-1 levels.

In this study, Byrd and his research team followed the development of the CLL-like disease in the mouse strain and found that the malignant mouse cells show many of the molecular characteristics of human CLL cells, such as expression of proteins called Bcl-2, Akt and normal p53.

The study also shows that the mouse disease mirrors CLL patients in its response to the drug fludarabine, including the development of resistance.

"This suggests that we can use this model to study the molecular changes that lead to fludarabine resistance and perhaps learn how to circumvent it," says first author Amy J. Johnson, research scientist in Byrd's laboratory.


'"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
22-Aug-2006


Page: 1 2

Related biology news :

1. Mouse model advances understanding of synovial sarcoma
2. Mouse FH knockout resembles human renal cell cancer
3. Mouse stem cell line advance suggests potential for IVF-incompetent eggs
4. Mouse model underestimates the critical role of Tyk2 in human immune system
5. Mouse DNA to aid biomedical research
6. Mouse strain with gene stutter will help leukemia research
7. Knockout Mouse Project
8. NIH launches Knockout Mouse Project
9. Mouse, frog and bird put Snail and Slug to different uses
10. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk
11. Mouse to man: The story of chromosomes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio ... findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease ... hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, this ...
(Date:7/1/2020)... SOMERSET, N.J. (PRWEB) , ... July 01, 2020 ... ... today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility ... with the company’s existing Japanese clinical supply facility located in Kakegawa, the new ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... announced that it has entered into a multi-year contract with Merus N.V., ... their translational and clinical research strategy to discover and develop ground-breaking drugs. ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... SOMERSET, N.J (PRWEB) , ... July 29, 2020 ... ... editing company, and Catalent, the leading global provider of advanced delivery technologies, development, ... products, today announced that they have entered into a strategic partnership whereby Catalent ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... sciences industry, today announced the release of its signature product called Beacon ... Liaisons (MSLs) and other field medical professionals. , Beacon helps MSLs ...
(Date:7/18/2020)... ... , ... “We are thrilled to deliver this new technology to the industry” ... kind on the market and we were pleased that the IFT jury recognized that.” ... ingredients, creating a natural way to extend the shelf life and improve the safety ...
(Date:7/10/2020)... LORTON, Va. (PRWEB) , ... July 08, 2020 ... ... laboratory testing services and products, announces a significant expansion of laboratory operations through ... robust collection for agencies implementing testing programs. , Bode-CARES provides ...
Breaking Biology Technology:
Cached News: